Cited by 5,892Schizophrenia research and treatmentMental Health and PsychiatryBipolar Disorder and Treatment

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Open access

Lieberman, Jeffrey A., Stroup, T. Scott, McEvoy, Joseph P., Swartz, Marvin S., Rosenheck, Robert A., Perkins, Diana O., Keefe, Richard S.E., Davis, Sonia M., Davis, Clarence E., Lebowitz, Barry D., Severe, Joanne, Hsiao, John K.·2005·New England Journal of Medicine

DOI 10.1056/nejmoa051688

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. METHODS: A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. The primary aim was to delineate differences in the overall effectiveness of these five treatments. RESULTS: Overall, 74 percent of patients discontinued the study medication before 18 months (1061 of the 1432 patients who received at least one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone, and 79 percent of those assigned to ziprasidone. The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P<0.001) or risperidone (P=0.002) group, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group. The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P=0.04); olanzapine was associated with more discontinuation for weight gain or metabolic effects, and perphenazine was associated with more discontinuation for extrapyramidal effects. CONCLUSIONS: The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons. Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone. Olanzapine was associated with greater weight gain and increases in measures of glucose and lipid metabolism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa051688

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Untitled work
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
Geddes, J. R., Freemantle, N., Harrison, P. J., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,056
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,022
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Self-citation
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
Leucht, S., Pitschel‐Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 795

Flagged first, then by citations

Show all 32 references

Sorted by citations

Items 701–800 of 1,049

Generating comparative evidence on new drugs and devices after approval
Cipriani, A., Ioannidis, J. P. A., Rothwell, P. M., Glasziou, P., Li, T., Hernandez, A. F., Tomlinson, A., Simes, R. J., & Naci, H. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33177-0 · Cited by 89
From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone
Masand, P. S., Nemeroff, C. B., Newcomer, J. W., Lieberman, J. A., Schatzberg, A. F., Weiden, P. J., Kilts, C. D., Harvey, P. D., & Daniel, D. G. (2005) · CNS Spectrums · doi:10.1017/s1092852900019842 · Cited by 89
Self-citation
Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring
Ansermot, N., Brawand-Amey, M., Kottelat, A., & Eap, C. B. (2013) · Journal of Chromatography A · doi:10.1016/j.chroma.2012.12.071 · Cited by 89
Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
Hirota, T., Veenstra-VanderWeele, J. M., Hollander, E., & Kishi, T. (2013) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-013-1952-2 · Cited by 89
Pharmacologic and Nonpharmacologic Strategies for Weight Gain and Metabolic Disturbance in Patients Treated with Antipsychotic Medications
Faulkner, G., & Cohn, T. A. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100805 · Cited by 89
Use Of Atypical Antipsychotic Drugs For Schizophrenia In Maine Medicaid Following A Policy Change
Soumerai, S. B., Zhang, F., Ross‐Degnan, D., BALL, D. E., LeCates, R. F., Law, M. R., Hughes, T. E., Chapman, D., & Adams, A. S. (2008) · Health Affairs · doi:10.1377/hlthaff.27.3.w185 · Cited by 89
Epigenetic mechanisms in schizophrenia
Akbarian, S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.3/sakbarian · Cited by 89
Adaptive Interventions in Child and Adolescent Mental Health
Almirall, D., & Chronis-Tuscano, A. M. (2016) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2016.1152555 · Cited by 89
Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management
Fang, F., Sun, H., Wang, Z., Ren, M., Calabrese, J. R., & Gao, K. (2016) · CNS Drugs · doi:10.1007/s40263-016-0352-5 · Cited by 89
Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data
Rohracher, A., Zimmermann, G., Villanueva, V., Garamendi, Í., Sander, J. W. A. S., Wehner, T., Shankar, R., Ben‐Menachem, E., Brodie, M. J., Pensel, M. C., et al. (2018) · Epilepsia · doi:10.1111/epi.14520 · Cited by 89
Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics
Heres, S., Lambert, M., & Vauth, R. (2014) · European Psychiatry · doi:10.1016/s0924-9338(14)70001-x · Cited by 88
Evidence for genetic contribution to the increased risk of type 2 diabetes in schizophrenia
Hackinger, S., Prins, B. P., Mamakou, V., Zengini, E., Marouli, E., Brčić, L., Serafetinidis, I., Lamnissou, K., Kontaxakis, V. P., Dedoussis, G. V., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0304-6 · Cited by 88
Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors
da Silva, N. R., Gomes, F. V., Sonego, A. B., da Silva, N. R., & Guimarães, F. S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104749 · Cited by 88
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study
Feng, Y., Pollock, B. G., Coley, K. C., Marder, S. R., Miller, D. D., Kirshner, M. A., Aravagiri, M., Schneider, L. S. S., & Bies, R. R. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03276.x · Cited by 88
Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments
Chien, W. T., & Yip, A. L. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s37485 · Cited by 88
Strategies for Maximizing Clinical Effectiveness in the Treatment of Schizophrenia
Tandon, R., Targum, S. D., Nasrallah, H. A., & ROSS, R. W. (2006) · Journal of Psychiatric Practice · doi:10.1097/00131746-200611000-00003 · Cited by 88
Comparative Effectiveness of Antipsychotic Drugs
Lieberman, J. A. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1069 · Cited by 88
Self-citation
Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives
Carrizo, E., Fernández, V., Quintero, J., Connell, L., Rodríguez, Z., Mosquera, M., Acosta, A., & Baptista, T. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.03.004 · Cited by 88
MEF2C transcription factor is associated with the genetic and epigenetic risk architecture of schizophrenia and improves cognition in mice
Mitchell, A., Javidfar, B., Pothula, V., Ibi, D., Shen, E., Peter, C. J., Bicks, L. K., Fehr, T., Jiang, Y., Brennand, K., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.254 · Cited by 88
Report From the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia
Keefe, R. S. E., Vinogradov, S., Medalia, A. A., Silverstein, S. M., Bell, M. D., Dickinson, D., Ventura, J., Marder, S. R., & Stroup, T. S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq010 · Cited by 87
Self-citation
The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
Nasrallah, H. A., Earley, W. R., Cutler, A. J., Wang, Y., Lu, K., Laszlovszky, I., Németh, G., & Durgam, S. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1459-z · Cited by 87
A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
Citrome, L., McEvoy, J. P., Todtenkopf, M. S., McDonnell, D., & Weiden, P. J. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s209284 · Cited by 87
Self-citation
Thirty years of research on negative symptoms of schizophrenia: A scientometric analysis of hotspots, bursts, and research trends
Sabé, M., Chen, C., Perez, N., Solmi, M., Mucci, A., Galderisi, S., Strauss, G. P., & Kaiser, S. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104979 · Cited by 87
Multivariate Phenotype Association Analysis by Marker‐Set Kernel Machine Regression
Maity, A., Sullivan, P. F., & Tzeng, J. (2012) · Genetic Epidemiology · doi:10.1002/gepi.21663 · Cited by 87
Genome-wide association study of antipsychotic-induced QTc interval prolongation
Åberg, K. A., Adkins, D. E., Liu, Y., McClay, J. L., Bukszár, J., Jia, P., Zhao, Z., Perkins, D. O., Stroup, T. S., Lieberman, J. A., et al. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.76 · Cited by 87
Self-citation
Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer’s Disease Patients: The CATIE-AD Study
Zheng, L., Mack, W. J., Dagerman, K., Hsiao, J., Lebowitz, B. D., Lyketsos, C. G., Stroup, T. S., Sultzer, D. L., Tariot, P. N., Vigen, C. L. P., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08081218 · Cited by 87
Self-citation
The association between weight change and symptom reduction in the CATIE schizophrenia trial
Hermes, E. D. A., Nasrallah, H. A., Davis, V. G., Meyer, J. M., McEvoy, J. P., GOFF, D. C., Thomas, S., Stroup, T. S., Swartz, M. S., Lieberman, J. A., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.022 · Cited by 87
Self-citation
Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia
Haukka, J. K., Tiihonen, J., Härkänen, T., & Lönnqvist, J. K. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1579 · Cited by 87
Animal models of gene–environment interactions in schizophrenia
Ayhan, Y., Sawa, A., Ross, C. A., & Pletnikov, M. V. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.010 · Cited by 87
The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum
Melka, M. G., Laufer, B. I., McDonald, P., Castellani, C. A., Rajakumar, N., O’Reilly, R., & Singh, S. M. (2014) · Clinical Epigenetics · doi:10.1186/1868-7083-6-1 · Cited by 87
Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients
Vernon, M., Revicki, D. A., Awad, A. G., Dirani, R. D., Panish, J. M., Canuso, C. M., Grinspan, A., Mannix, S., & Kalali, A. H. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.01.021 · Cited by 87
Efficacy, Acceptability and Tolerability of Antipsychotics in Patients with Schizophrenia and Comorbid Substance Use. A Systematic Review and Meta-Analysis
Krause, M., Huhn, M., Schneider-Thoma, J., Bighelli, I., Gutsmiedl, K., & Leucht, S. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.1105 · Cited by 86
Trajectories of the course of schizophrenia: From progressive deterioration to amelioration over three decades
Levine, S. Z., Lurie, I., Kohn, R., & Levav, I. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.10.026 · Cited by 86
Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia
Canuso, C. M., Dirks, B., Carothers, J. L., Kosik‐Gonzalez, C., Bossie, C. A., Zhu, Y., Damaraju, C. V., Kalali, A. H., & Mahmoud, R. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08040613 · Cited by 86
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia
Martin, W. F., Correll, C. U., Weiden, P. J., Jiang, Y., Pathak, S., DiPetrillo, L., Silverman, B. L., & Ehrich, E. W. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030280 · Cited by 86
Non‐psychiatric health problems among psychiatric inpatients with intellectual disabilities
Charlot, L., Abend, S. L., Ravin, P., Mastis, K., Hunt, A., & Deutsch, C. (2010) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2010.01294.x · Cited by 86
Weight Considerations in Psychotropic Drug Prescribing and Switching
Hasnain, M., & Vieweg, W. V. R. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.09.2706 · Cited by 86
Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial)
Ballard, C. G., Brown, R. G., Fossey, J., Douglas, S., Bradley, P., Hancock, J., James, I. A., Juszczak, E., Bentham, P., Burns, A. S., et al. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181b0f8c0 · Cited by 86
Improving psychological adjustment following a first episode of psychosis: A randomised controlled trial of cognitive therapy to reduce post psychotic trauma symptoms
Jackson, C., Trower, P., Reid, I., Smith, J., Hall, M., Townend, M., Barton, K., Jones, J., Ross, K., Russell, R., et al. (2009) · Behaviour Research and Therapy · doi:10.1016/j.brat.2009.02.009 · Cited by 86
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents
Calarge, C. A., Ellingrod, V. L., Ación, L., Miller, D. D., Moline, J., Tansey, M., & Schlechte, J. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328329a60f · Cited by 86
Diabetes and schizophrenia – effect of disease or drug? Results from a randomized, double‐blind, controlled prospective study in first‐episode schizophrenia
Saddichha, S., Manjunatha, N., Ameen, S., & Akhtar, S. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01158.x · Cited by 86
Pharmacogenetics in psychiatry: translating research into clinical practice
Ak, M., Zhang, J.-P., & Lencz, T. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.146 · Cited by 85
Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress
Lin, C., & Lane, H. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00093 · Cited by 85
Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis
Huhn, M., Nikolakopoulou, A., Schneider‐Thoma, J., Krause, M., Samara, M. T., Peter, N. L., Arndt, T. J., Bäckers, L., Rothe, P., Cipriani, A., et al. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18306 · Cited by 85
The SOHO (Schizophrenia Outpatient Health Outcome) Study
Haro, J. M., & Salvador‐Carulla, L. (2006) · CNS Drugs · doi:10.2165/00023210-200620040-00003 · Cited by 85
The heterogeneity of antipsychotic response in the treatment of schizophrenia
Case, M., Stauffer, V. L., Ascher‐Svanum, H., Conley, R. R., Kapur, S., Kane, J. M., Kollack‐Walker, S., Jacob, J., & Kinon, B. J. (2010) · Psychological Medicine · doi:10.1017/s0033291710001893 · Cited by 85
Ziprasidone for Schizophrenia and Bipolar Disorder: A Review of the Clinical Trials
Greenberg, W. M., & Citrome, L. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00008.x · Cited by 85
Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas
Perry, K. W., Falcone, J. F., Fell, M. J., Ryder, J. W., Yu, H. Y., Love, P. L., Katner, J., Gordon, K. D., Wade, M. R., Man, T., et al. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.016 · Cited by 85
Insomnia Comorbid to Severe Psychiatric Illness
Soehner, A. M., Kaplan, K. A., & Harvey, A. G. (2013) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2013.04.007 · Cited by 85
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J. A., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S. S., Fang, B., Peterson, E., Aquino, P. R., et al. (2012) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.10.2.194 · Cited by 85
Decision-Theoretic Psychiatry
Huys, Q. J. M., Guitart‐Masip, M., Dolan, R. J., & Dayan, P. (2015) · Clinical Psychological Science · doi:10.1177/2167702614562040 · Cited by 85
Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study
Gründer, G., Heinze, M., Cordes, J., Mühlbauer, B., Juckel, G., Schulz, C., Rüther, E., & Timm, J. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00085-7 · Cited by 85
Balancing Efficacy and Safety in Treatment with Antipsychotics
Correll, C. U. (2007) · CNS Spectrums · doi:10.1017/s1092852900026298 · Cited by 85
Schizophrenia: The drug deadlock
Abbott, A. (2010) · Nature · doi:10.1038/468158a · Cited by 85
Pragmatic vs explanatory trials: the Pragmascope tool to help measure differences in protocols of mental health randomized controlled trials
Tosh, G., Soares-Weiser, K., & Adams, C. E. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/gtosh · Cited by 84
Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning
Kaneko, K. (2018) · Yonago acta medica · doi:10.33160/yam.2018.06.001 · Cited by 84
New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia
Wagner, A. M., Shemer, Z., Touloumi, O., Lagoudaki, R., Giladi, E., Andrieux, A., Grigoriadis, N., & Gozes, I. (2014) · Autophagy · doi:10.4161/15548627.2014.984274 · Cited by 84
Quetiapine in the treatment of schizophrenia and related disorders
Riedel, M. J., Müller, N., Strassnig, M., Spellmann, I., Severus, E., & Möller, H. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.2.219 · Cited by 84
Risperidone versus olanzapine for schizophrenia
Jayaram, M., Hosalli, P., & Stroup, T. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005237.pub2 · Cited by 83
Self-citation
Shared understanding in psychiatrist–patient communication: Association with treatment adherence in schizophrenia
McCabe, R., Healey, P. G. T., Priebe, S., Lavelle, M., Dodwell, D., Laugharne, R. A., Snell, A., & Bremner, S. A. (2013) · Patient Education and Counseling · doi:10.1016/j.pec.2013.05.015 · Cited by 83
Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with Schizophrenia in Quebec and Saskatchewan: A retrospective database study
Ward, A. J., Ishak, K. J., Proskorovsky, I., & Caro, J. J. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.002 · Cited by 83
Atypical Antipsychotics for the Treatment of Delirious Elders
Ozbolt, L. B., Paniagua, M. A., & Kaiser, R. M. (2008) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2007.08.007 · Cited by 83
Reasons to Prescribe Antipsychotics for the Behavioral Symptoms of Dementia: A Survey in Dutch Nursing Homes Among Physicians, Nurses, and Family Caregivers
Cornegé‐Blokland, E., Kleijer, B. C., Hertogh, C. M. P. M., & van Marum, R. J. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.10.004 · Cited by 83
Dopamine Depletion of the Prefrontal Cortex Induces Dendritic Spine Loss: Reversal by Atypical Antipsychotic Drug Treatment
Wang, H.-D., & Deutch, A. Y. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301521 · Cited by 83
Effectiveness of second generation antipsychotics: A systematic review of randomized trials
Johnsen, E., & Jørgensen, H. A. (2008) · BMC Psychiatry · doi:10.1186/1471-244x-8-31 · Cited by 83
The Association Between Comorbid Autism Spectrum Disorders and Antipsychotic Treatment Failure in Early-Onset Psychosis
Downs, J. M., Lechler, S., Dean, H., Sears, N., Patel, R., Shetty, H., Simonoff, E. A., Hotopf, M. H., Ford, T. J., Díaz‐Caneja, C. M., et al. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11422 · Cited by 83
A 24-Week Randomized Study of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenia or Schizoaffective Disorder in Patients with Prominent Depressive Symptoms
Kinon, B. J., Lipkovich, I. A., Edwards, S. B., Adams, D. H., Ascher‐Svanum, H., & Siris, S. G. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000204137.82298.06 · Cited by 83
Progress in Defining Optimal Treatment Outcome in Schizophrenia
Remington, G. J., Foussias, G., & Agid, O. (2009) · CNS Drugs · doi:10.2165/11530250-000000000-00000 · Cited by 82
Prefrontal cognitive systems in schizophrenia : Towards human genetic brain mechanisms
Tan, H. Y., Callicott, J. H., & Weinberger, D. R. (2009) · Cognitive Neuropsychiatry · doi:10.1080/13546800903091665 · Cited by 82
Normal Pressure Hydrocephalus Presenting as Othello Syndrome: Case Presentation and Review of the Literature
Yusim, A., Anbarasan, D., Bernstein, C., Boksay, I., Dulchin, M., Lindenmayer, J., Saavedra-Velez, C., Shapiro, M., & Sadock, B. J. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111820 · Cited by 82
Correlates of Future Violence in People Being Treated for Schizophrenia
Buchanan, A. W., Sint, K., Swanson, J. W., & Rosenheck, R. A. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18080909 · Cited by 82
Self-citation
Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects
Ohno, Y., Kunisawa, N., & Shimizu, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01045 · Cited by 82
Patterns of pharmacotherapy for bipolar disorder: A GBC survey
Singh, B., Yocum, A. K., Strawbridge, R., Burdick, K. E., Millett, C. E., Peters, A. T., Sperry, S. H., Fico, G., Vieta, E., Verdolini, N., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13366 · Cited by 82
Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia
Polymeropoulos, M. H., Licamele, L., Volpi, S., Mack, K., Mitkus, S. N., Carstea, E. D., Getoor, L. C., Thompson, A. D., & Lavedan, C. N. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.025 · Cited by 82
Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: A population-based study
Liao, C.-H., Chang, C.-S., Wei, W.-C., Chang, S., Liao, C., Lane, H., & Sung, F.-C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.12.007 · Cited by 82
Serotonin 2A receptor antagonists for treatment of schizophrenia
Ebdrup, B. H., Rasmussen, H., Arnt, J., & Glenthoj, B. Y. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601738 · Cited by 83
Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers
Fiedorowicz, J. G., Miller, D. D., Bishop, J. R., Calarge, C. A., Ellingrod, V. L., & Haynes, W. G. (2012) · Current Psychiatry Reviews · doi:10.2174/157340012798994867 · Cited by 82
A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter
Amato, D., Canneva, F., Cumming, P. D., Maschauer, S., Groos, D., Dahlmanns, J. K., Grömer, T. W., Chiofalo, L., Dahlmanns, M., Zheng, F., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0114-5 · Cited by 82
The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics
Binder, M. D., Sermon, J., Geerts, P., Vansteelandt, K., Peuskens, J., & Detraux, J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0269-4 · Cited by 81
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies
Emsley, R. A., Berwaerts, J., Eerdekens, M., Kramer, M. L., Lane, R., Lim, P., Hough, D., & Palumbo, J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328314e1f3 · Cited by 81
Antipsychotic Prescribing Pathways, Polypharmacy, and Clozapine Use in Treatment of Schizophrenia
Gören, J. L., Meterko, M. M., Williams, S. A., Young, G. J., Baker, E. H., Chou, C.-H., Kilbourne, A. M., & Bauer, M. S. (2013) · Psychiatric Services · doi:10.1176/appi.ps.002022012 · Cited by 81
The expanding role of somatostatin analogs in the management of neuroendocrine tumors.
Wolin, E. M. (2012) · Europe PMC (PubMed Central) · Cited by 81
Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats
Skrede, S., Fernø, J., Vazquez, M. J., Fjær, S., Pavlin, T., Lunder, N., Vidal‐Puig, A., Diéguez, C., Berge, R. K., López, M., et al. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001271 · Cited by 81
Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders
Abbas, A. I., & Roth, B. L. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802532707 · Cited by 81
Immune system and glucose metabolism interaction in schizophrenia: A chicken–egg dilemma
Steiner, J. H., Bernstein, H., Schiltz, K., Müller, U., Westphal, S., Drexhage, H. A., & Bogerts, B. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.09.016 · Cited by 81
Genetic Variation Throughout the Folate Metabolic Pathway Influences Negative Symptom Severity in Schizophrenia
Roffman, J. L., Brohawn, D. G., Nitenson, A. Z., Macklin, E. A., Smoller, J. W., & GOFF, D. C. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr150 · Cited by 81
Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head–head comparisons
Haddad, P. M., Das, A., Keyhani, S., & Chaudhry, I. B. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111424929 · Cited by 81
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder
Keks, N. A., Ingham, M., Khan, A., & Karcher, K. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.017020 · Cited by 81
Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability
Amato, D., Vernon, A. C., & Papaleo, F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.027 · Cited by 81
Risk of weight gain for specific antipsychotic drugs: a meta-analysis
Spertus, J. V., Horvitz-Lennon, M. V., Abing, H. K., & Normand, S. T. (2018) · Schizophrenia · doi:10.1038/s41537-018-0053-9 · Cited by 81
Schizophrenia in late life: emerging issues
Folsom, D. P., Lebowitz, B. D., Lindamer, L. A., Palmer, B. W., Patterson, T. L., & Jeste, D. V. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.1/dfolsom · Cited by 81
Self-citation
Positive and negative effects of antipsychotic medication: an international online survey of 832 recipients
Read, J., & Williams, J. (2019) · Current Drug Safety · doi:10.2174/1574886314666190301152734 · Cited by 80
Mental health policy in the liberal state: The example of the United States
Grob, G. N. (2008) · International Journal of Law and Psychiatry · doi:10.1016/j.ijlp.2008.02.003 · Cited by 80
The Evaluation and Management of Patients with First-Episode Schizophrenia: A Selective, Clinical Review of Diagnosis, Treatment, and Prognosis
Freudenreich, O., Holt, D. J., Cather, C., & GOFF, D. C. (2007) · Harvard Review of Psychiatry · doi:10.1080/10673220701679804 · Cited by 80
Telemedicine interventions for medication adherence in mental illness: A systematic review
Basit, S. A., Mathews, N., & Kunik, M. E. (2019) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2019.11.004 · Cited by 80
Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention
Agid, O., Foussias, G., & Remington, G. J. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.499125 · Cited by 80
Unraveling Monoamine Receptors Involved in the Action of Typical and Atypical Antipsychotics on Glutamatergic and Serotonergic Transmission in Prefrontal Cortex
López-Gil, X., Artigas, F., & Adell, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361416 · Cited by 80
Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies
Ostuzzi, G., Bighelli, I., So, R., Furukawa, T. A., & Barbui, C. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.010 · Cited by 80
Cognitive behaviour therapy for psychosis
Kuipers, E., & Bebbington, P. (2006) · Epidemiology and Psychiatric Sciences · doi:10.1017/s1121189x00002153 · Cited by 80
New drug developments in psychosis: Challenges, opportunities and strategies
Keshavan, M. S., Lawler, A. N., Nasrallah, H. A., & Tandon, R. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.07.004 · Cited by 79

Authors: Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K.
Affiliations: New York State Psychiatric Institute (US)
Duke University (US)
Yale University (US)
University of North Carolina at Chapel Hill (US)
National Institutes of Health (US)
ORCID: Lieberman, Jeffrey A.
Stroup, T. Scott
McEvoy, Joseph P.
Swartz, Marvin S.
Rosenheck, Robert A.
Perkins, Diana O.
Keefe, Richard S.E.
Lebowitz, Barry D.
Hsiao, John K.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-09-22
Volume: 353
Issue: 12
Pages: 1209-1223
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa051688
OpenAlex: W2159155203
Cited by: 5,892
References: 32
Citations by year: 2026: 95 · 2025: 89 · 2024: 135 · 2023: 129 · 2022: 191 · 2021: 166 · 2020: 338 · 2019: 207 · 2018: 211 · 2017: 220 · 2016: 231 · 2015: 277 · 2014: 325 · 2013: 361 · 2012: 379
FWCI: 258.86
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
GlaxoSmithKline
Case Western Reserve University
Foundation of Hope for Research and Treatment of Mental Illness
Otsuka Pharmaceutical
National Institutes of Health (n01mh90001-21-0-0)
University of North Carolina at Chapel Hill
National Institute of Mental Health (N01 MH90001, MH90001)
Janssen Pharmaceuticals
School of Medicine, University of North Carolina at Chapel Hill
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: schizophrenia, antipsychotic drugs, atypical antipsychotics, typical antipsychotics, perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, treatment discontinuation, treatment efficacy, adverse effects, weight gain, metabolic effects, extrapyramidal symptoms, chronic schizophrenia, double-blind comparison, long-term treatment
MeSH terms: Quetiapine Fumarate, Olanzapine, Adult, Benzodiazepines, Chronic Disease, Dibenzothiazepines, Double-Blind Method, Female, Humans, Lipids, Male, Patient Compliance, Perphenazine, Piperazines, Schizophrenia, Thiazoles, Antipsychotic Agents, Weight Gain, Proportional Hazards Models, Treatment Outcome, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks